CDK inhibitors in hormone receptor positive advanced breast cancer | Zendy

Bilge Aktaş | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CDK inhibitors in hormone receptor positive advanced breast cancer

Author(s) -

Bilge Aktaş

Publication year - 2015

Publication title -

marmara medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.112

H-Index - 11

ISSN - 1309-9469

DOI - 10.5472/mmj.77406

Subject(s) - medicine , hormone receptor , breast cancer , hormone , cancer , receptor , oncology , cancer research

Endocrine treatment is the current first line treatment in ER+ advanced breast cancer with a requirement of predictive biomarkers to the treatment and different approaches for endocrine resistance risk. Cyclin dependent kinases (CDKs) are regulating each step of cellular division in mammalian cell cycle and are hyperactivated in cancer cells causing cancer progression. Next generation pan-CDK inhibitors are in clinical development, while clinical trials in breast cancer, particularly in ER+ subtype where the greatest growth inhibition has been observed. Here I will review the data from this new class of drugs. Keywords: CDK inhibitors, Hormone positive advanced breast cancer, Targeted therapies, Palbociclib, Endocrine therapy resistance

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research